Add like
Add dislike
Add to saved papers

Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion.

OBJECTIVE: The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion, yet the standard urate-lowering therapy (ULT) recommendation is first line xanthine oxidase inhibition (XOI) irrespective of the cause of hyperuricemia. Here, we conducted a comparative effectiveness clinical trial of first line un-titrated, low-dose benzbromarone uricosuric therapy vs. XOI ULT with low-dose febuxostat in gout with renal uric acid underexcretion.

METHODS: A prospective, randomized, single-center, open-labeled trial of men with gout and renal uric acid underexcretion (defined as fractional excretion of urate <5.5% and uric acid excretion ≤600 mg/day/1.73m2 ) was conducted. We randomly assigned 196 participants to low-dose benzbromarone 25 mg daily (LDBen) or low-dose febuxostat 20 mg daily (LDFeb) for 12 weeks. All participants received daily urine alkalization with oral sodium bicarbonate. The primary endpoint was rate of achieving serum urate (SU) target <6 mg/dL.

RESULTS: More participants in the LDBen group achieved the serum urate target than LDFeb (61% vs. 32%, P<0.001). Adverse events, including gout flares and urolithiasis, did not differ between groups, with the exception of more transaminase elevation in the LDFeb group (LDBen 4% vs. LDFeb 15%, P=0.008).

CONCLUSION: Compared to LDFeb, LDBen had superior urate-lowering and similar safety in the relatively young and healthy patients with gout of renal uric acid underexcretion type.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app